Date: 2011-09-19
Type of information: Fundraising
Company: Malcisbo (Switzerland)
Investors: Private investors - Business Angels - Zürcher Kantonalbank Startup Finance (Switzerland) - Redalpine Venture Partners AG (Switzerland)
Amount: CHF 3.6 million (€3 million)
Funding type: seed financing round
Planned used: Malcisbo, domiciled in Zurich, Switzerland, was incorporated in May 2010 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich). Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Its focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with our glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo’s first vaccines target the medical areas of human Campylobacter infections (prevention of human food poisoning) and ruminant Haemonchus infections (prevention of economic loss during food production).
Others: Malcisbo has successfully closed its seed financing round. The initial target of CHF 2.4 million. was substantially exceeded. Private investors, Business Angels, Zürcher Kantonalbank Startup Finance and Redalpine Venture Partners AG have invested in total a sum of CHF 3.6 million in the company. In parallel the company was granted a substantial research contribution by CTI.
Therapeutic area: Infectious diseases
